Commercialization of Photobiomodulation for Vision Impairment in Dry Age-Related Macular Degeneration Patients


To conduct a clinical trial of a dry age-related macular degeneration therapy

Anticipated Impact: 

The first effective treatment for dry age-related macular degeneration, which will be safe, inexpensive, and easily tolerated


The "dry" form of age-related macular degeneration (AMD) has no treatment, yet affects approximately 10 million patients in the US. Exposing the retina to specific wavelengths of LED light delivered through the eye has been demonstrated to be safe and effective in preliminary work. An LSDF Proof of Concept grant supported development of a sophisticated prototype device and testing of light delivery in cadaver eyes. Four more devices will be built and used to conduct a 60-patient (120 eye) multicenter controlled trial to demonstrate effectiveness at improving vision acuity and contrast. Matching funds will come entirely from accredited investors.

Collaborating organizations: Product Creation Studio, Qualitel, TFS International, University of Toronto

Age-related Macular Degeneration Treatment

Grant Update

Principal Investigator:
Clark Tedford
Grantee Organization:
LumiThera, Inc.
Grant Title:
Commercialization of Photobiomodulation for Vision Impairment in dry Age-Related Macular Degeneration Patients
Grant Cohort and Year:
2015 Matching (05)
Grant Period:
05/27/2015 - 05/26/2017 (Completed)
Grant Amount:
The LSDF commercialization grant allowed LumiThera to create a commercial/clinical LED instrument to non-invasively treat ocular disease in the elderly with age related macular degeneration. The LT-300 LED device was completed and is now undergoing clinical testing in a NIH supported clinical trial.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 23, 34, 36, 37, 38, 43, 46

Health Impacts

Age-related Macular Degeneration Treatment

Oct 15, 2015
Kitsap Sun/Kitsap Peninsula Business Journal